JAN (JAN) to Issue Monthly Dividend of $0.05 on October 28th

JAN (NYSE:JAN) announced a monthly dividend on Friday, September 11th. Shareholders of record on Friday, October 16th will be paid a dividend of $0.0475 per share on Wednesday, October 28th. This represents a $0.57 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Friday, October 16th.

JAN Stock Up 0.5%

Shares of JAN stock opened at $28.87 on Wednesday. JAN has a one year low of $22.76 and a one year high of $32.83. The company’s 50-day simple moving average is $30.12 and its 200-day simple moving average is $28.03.

JAN (NYSE:JAN) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The company had revenue of $216.46 million during the quarter, compared to analyst estimates of $203.32 million. JAN’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Sell-side analysts predict that JAN will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On JAN

A number of large investors have recently bought and sold shares of JAN. Greenland Capital Management LP acquired a new position in JAN in the second quarter valued at approximately $575,000. Readystate Asset Management LP bought a new position in shares of JAN during the second quarter valued at approximately $1,724,000. WINTON GROUP Ltd acquired a new stake in shares of JAN during the 2nd quarter worth approximately $2,985,000. Wellington Management Group LLP acquired a new stake in shares of JAN during the 2nd quarter worth approximately $8,739,000. Finally, Engineers Gate Manager LP bought a new stake in shares of JAN in the 2nd quarter worth approximately $15,274,000. Institutional investors own 6.27% of the company’s stock.

About JAN

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.